MedTech Open Innovation Testbed open call for SMEs tackling COVID-19

DEADLINE: 02 October 2020

Small and Medium-sized Enterprises (SMEs) and other business were put at high risk by the economic slowdown caused by the COVID-19 pandemic across Europe.

Consequently, the three European Union-funded MedTech Open Innovation Testbed (OITB) projects - TBMED, MDOT and SAFE-N-MEDTECH  - decided to work together to provide services to selected innovators and help them reach the market faster.

The three OITB projects have allocated part of their budgets to include new case studies in their on-going projects. Innovative SMEs, companies, start-ups and applied research institutions working on the development of solutions to fight the virus are invited to apply to this call.

    The concept of OITBs to forge pan-European innovation networks tailored to the specific needs of novel medical technologies makes them the ideal instruments for quickly finding solutions under urgent conditions such as the COVID-19 outbreak.

    The three OITBs thus initiate a call for expressions of interest from MedTech SMEs performing COVID-19-related developments. Support will be provided in the following ways:

    • TBMED offers services to developers from the high-risk medical devices sector, particularly with regard to characterisation, prevention, diagnosis, treatment, follow-up and the forecast of patient prognosis related to COVID-19. Such services include, among others, early dialogues with the Basque HTA office, expert advice for regional and/or multinational clinical trials on COVID-19 and the assessment of needs of such companies regarding clinical trials.
    • MDOT members who develop routines and processes to accelerate the conformity assessment of medical devices, offer consultation regarding regulatory affairs and technology development in the fields of inhalation technologies and environmental sensors.
    • SAFE-N-MEDTECH with its key expertise in nano-enabled medical technologies, offers characterisation, preclinical validation, access to biobanks and patient samples, scale up and regulatory support, technology assessment and horizon scanning.

    Deadline for submission of applications is October 2, 2020  (17:00 CEST).

    Share this Article